misleading statements

PayPal faces securities lawsuit after CEO ousted, 2027 targets withdrawn. Stock plunged 20%, erasing $10B market cap amid allegations of investor misleading.

The Schall Law Firm investigates Neumora Therapeutics ($NMRA) for potential securities fraud involving false statements or material information omissions.

$ODD stock crashes 49% after revealing 30% Q1 revenue decline tied to advertising partner algorithm shift. Securities lawsuit filed over disclosure failures.

Class actions filed against $PYPL over false revenue projections and $RGENX after FDA clinical hold on gene therapy following safety concerns.

China Liberal Education Holdings faces class action securities fraud lawsuit alleging pump-and-dump scheme and failure to disclose material information during January 2025.

Class action lawsuit filed against Inovio Pharmaceuticals ($INO) for allegedly making false statements about INO-3107 treatment and manufacturing capabilities, causing significant stock declines.

Class action lawsuit filed against $ALIT alleging executives made false statements about growth and cost cuts while concealing sales execution failures.

Class action lawsuit filed against $ALIT over alleged false statements on growth and cost-cutting. Stock fell 18.3% in August 2025, 38.2% in February 2026 following earnings misses.

Class action lawsuit filed against $UQRR alleging materially false statements about FDA approval and BLA timeline delays. Investors urged to join by April 13, 2026 deadline.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Portnoy Law Firm files class action against Camping World Holdings ($CWH) for allegedly making false statements about inventory management and consumer demand between April 2025 and February 2026.

Snowflake faces class action lawsuit alleging false statements about product efficiency, with stock down 18% during June 2023-February 2024 period. Lead plaintiff applications due April 2026.

Rosen Law Firm urges PomDoctor Ltd. investors with $100k+ losses to join securities fraud class action before April 7, 2026 deadline, alleging false statements and stock manipulation scheme.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

Rosen Law Firm files securities class action against Ultragenyx Pharmaceutical ($RARE) alleging false statements about setrusumab efficacy in clinical trials.

Law firm launches class action against $CWH over alleged misstatements on inventory management and demand forecasts between April 2025 and February 2026.

PayPal faces securities class action lawsuit alleging false 2027 financial guidance and concealed salesforce execution gaps. Lead plaintiff deadline: April 20, 2026.

$PLUG faces class action lawsuit alleging false statements about DOE funding and hydrogen production facilities. Investors can seek lead plaintiff status by April 3, 2026.

Class action lawsuit filed against $EOS alleging securities fraud over undisclosed production delays, quality control issues, and inadequate guidance during Nov 2025-Feb 2026 period.

Robbins LLP sues Franklin BSP Realty Trust ($FBRT) for allegedly misleading investors about dividend sustainability before cutting payout 44%.